1. The company saw net income of $24.5 million, up 133.9 percent from the same period a year prior.
2. The company acquired Bioness for $45 million on March 30.
3. The company updated its revenue guidance for 2021, driven by first-quarter results. Bioventus now expects full-year revenue of $394 million to $406 million.
4. Bioventus had an EBITDA of $11.1 million, down $3.2 million from the first quarter of 2020 — which their report said was driven by public company costs and higher selling expenses due to better-than-expected sales.
“Bioventus delivered better-than-expected first quarter revenue results, driven primarily by accelerating U.S. sales growth trends as we moved through the quarter, culminating with nearly 30 percent year-over-year growth in March,” said Ken Reali, CEO of Bioventu
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.